Patients For Affordable Drugs’ Post

📢🇺🇸Back in February, we discussed state-level solutions for drug costs, like Prescription Drug Affordability Boards. Today, we're diving into the first lawsuit of this kind: Amgen v. Colorado Prescription Drug Affordability Board. 🏛️💊 Colorado reviewed 604 drugs and found Enbrel unaffordable, starting a process to set a price cap. Amgen argues that this violates the Constitution, citing the Supremacy Clause, Commerce Clause, and Due Process clause. The outcome could impact similar efforts in other states. Stay tuned! 📈⚖️ Victor Agbafe #HealthcarePolicy #DrugPricing #AmgenVsColorado #AffordableMedicine #HealthLaw

Weekend reading: US's 340B Drug Pricing Program, already the second largest affordable drug pricing program is spiralling out of control as the scale is growing but the benefits are not reaching the patients Read more here: https://lnkd.in/gfTgqVGC

It's time for another episode/post of #Indiana's new drug pricing database! Indiana All Payer Claims Database: https://lnkd.in/gwXEWurD #Immunosuppressants this morning - let's pick on #1 - generic Aubagio or #teriflunomide. It's a drug used in many #MS patients. All time for the database, Indiana had 1,954 claims for this drug with an average cost of $3,004.36 per claim. Our costs at Mark Cuban Cost Plus Drug Company, PBC today, 9/4/24 for this drug: Teriflunomide 14 mg, #90 www.costplusdrugs.com (mail order) = $28.40 www.teamcubancard.com (local network #pharmacy) = $31.25 1,954 claims x $31.25 = $61,062.50 Savings: $5,870,525 - 61,062.50 = $5,809,462.50 That's another $5.8M we could have saved the State of Indiana. That could have been used for businesses to hire more employees, or pay employees more, or use the money on state plans to cover more lives. There is a better way!

Gazette: EDITORIAL: Capping Colorado’s prescription costs will backfire: If only there were a magic wand to tame the high cost of living in our inflationary economy. Instead, there are politicians — who merely pretend to possess such superhuman power. And their attempts to wield it inevitably backfire, sooner or later. Thus, our sense of impending doom after news that another high-priced prescription drug was officially declared “unaffordable” by Colorado’s groundbreaking Prescription Drug Affordability Review Board. The finding last Friday paves the way for the drug board to set an upper price limit that could be charged for the drug in our state. … As reported Monday in The Gazette by the Colorado Chamber of Commerce’s Sum & Substance news service, the board’s action was directed at Stelara, a medication that treats anti-inflammatory diseases affecting joints and bowels. It was developed and is manufactured by pharmaceutical giant Johnson & Johnson, and demand for it has been on the rise. Read more here. http://dlvr.it/T8Drr1 #Timnath #Colorado #TimnathChamber

If you believe that bigger leverage gets bigger drug discounts, we can assume that with ~20x more members, CVS Caremark should be getting a much lower net price for their Humira biosimilar than Blue Shield of California. So with CVS’s Humira biosimilar list price being at a minimum 2.5x higher than Blue Shield’s, does that mean that the overwhelming majority of the cost for Humira isn’t actually the drug itself? Rebates continue to be the chief pollutant of the U.S. prescription drug marketplace.

As the new administration gets ready to take office, here’s a sneak peek at how drug pricing and reimbursement policies might change.

While president-elect Trump has yet to articulate priorities with respect to drug pricing and reimbursement, his reform efforts during his prior administration and the ongoing bipartisan focus on drug affordability suggest that drug pricing will continue to be an area of focus. Here, we discuss key drug pricing programs and other areas to watch as the new administration takes shape: https://bit.ly/3VyDgdb

Each day, NHS patients take home 2.4 million generic and biosimilar drugs. To protect this vital sector, the incoming Government needs a dedicated off-patent sector policy, and an agreed systematic approach to reducing drug shortages. Read our manifesto for our full recommendations to the next Government: https://lnkd.in/eQduESts #GeneralElection24 #HealthPolicy #DrugShortages

DRUG PRICE NEGOTIATION ANALYSIS: It's unlikely that Congress will take up President Biden's call to expand the number of drugs up for Medicare price negotiation from 20 to 50 -- as he will do in tonight's State of the Union address. However, it is a good reminder that #pharma and #marketaccess teams should be thinking and scenario-planning for the possibility. Read our analysis below 👇 👇 👇 and contact Dina Steinfurth to gain a better perspective on navigating drug price negotiation.

Plans change every year. With the new yearly $2,000 cap on covered out-of-pocket drugs and the option to spread your prescription costs across the year, it’s even more important to review and compare your health and drug plan options. You could find a better plan for your needs and budget. https://lnkd.in/gqkNCurJ